Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs WOCKHARDT - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA WOCKHARDT DISHMAN PHARMA/
WOCKHARDT
 
P/E (TTM) x 25.1 -92.8 - View Chart
P/BV x 3.3 2.1 162.8% View Chart
Dividend Yield % 0.7 0.0 35,402.8%  

Financials

 DISHMAN PHARMA   WOCKHARDT
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
WOCKHARDT
Mar-18
DISHMAN PHARMA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs3741,012 37.0%   
Low Rs129532 24.3%   
Sales per share (Unadj.) Rs197.8355.9 55.6%  
Earnings per share (Unadj.) Rs21.2-60.3 -35.2%  
Cash flow per share (Unadj.) Rs34.7-46.8 -74.3%  
Dividends per share (Unadj.) Rs2.000.01 20,000.0%  
Dividend yield (eoy) %0.80 61,335.2%  
Book value per share (Unadj.) Rs179.9257.8 69.8%  
Shares outstanding (eoy) m80.69110.63 72.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.32.2 58.7%   
Avg P/E ratio x11.9-12.8 -92.7%  
P/CF ratio (eoy) x7.2-16.5 -43.9%  
Price / Book Value ratio x1.43.0 46.7%  
Dividend payout %9.40 -56,849.9%   
Avg Mkt Cap Rs m20,30685,379 23.8%   
No. of employees `0000.86.3 13.3%   
Total wages/salary Rs m5,3559,371 57.1%   
Avg. sales/employee Rs Th19,252.76,295.0 305.8%   
Avg. wages/employee Rs Th6,459.51,498.3 431.1%   
Avg. net profit/employee Rs Th2,064.1-1,066.3 -193.6%   
INCOME DATA
Net Sales Rs m15,96139,369 40.5%  
Other income Rs m2651,202 22.1%   
Total revenues Rs m16,22640,571 40.0%   
Gross profit Rs m4,10318 22,421.9%  
Depreciation Rs m1,0911,495 72.9%   
Interest Rs m9442,555 37.0%   
Profit before tax Rs m2,334-2,830 -82.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m624257 242.6%   
Profit after tax Rs m1,711-6,669 -25.7%  
Gross profit margin %25.70 55,306.9%  
Effective tax rate %26.7-9.1 -294.2%   
Net profit margin %10.7-16.9 -63.3%  
BALANCE SHEET DATA
Current assets Rs m11,01833,796 32.6%   
Current liabilities Rs m9,51726,917 35.4%   
Net working cap to sales %9.417.5 53.8%  
Current ratio x1.21.3 92.2%  
Inventory Days Days11079 139.3%  
Debtors Days Days3589 39.0%  
Net fixed assets Rs m16,30439,664 41.1%   
Share capital Rs m161553 29.2%   
"Free" reserves Rs m12,90727,968 46.1%   
Net worth Rs m14,51628,522 50.9%   
Long term debt Rs m4,18921,731 19.3%   
Total assets Rs m29,80581,620 36.5%  
Interest coverage x3.5-0.1 -3,228.3%   
Debt to equity ratio x0.30.8 37.9%  
Sales to assets ratio x0.50.5 111.0%   
Return on assets %8.9-5.0 -176.8%  
Return on equity %11.8-23.4 -50.4%  
Return on capital %17.5-7.7 -228.4%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,9529,807 50.5%   
Fx outflow Rs m6971,789 39.0%   
Net fx Rs m4,2558,019 53.1%   
CASH FLOW
From Operations Rs m2,786684 407.1%  
From Investments Rs m-1,5296,302 -24.3%  
From Financial Activity Rs m-941-7,695 12.2%  
Net Cashflow Rs m316-664 -47.7%  

Share Holding

Indian Promoters % 61.4 74.5 82.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 2.3 160.9%  
FIIs % 12.7 7.7 164.9%  
ADR/GDR % 0.0 0.1 -  
Free float % 22.1 15.4 143.5%  
Shareholders   46,261 67,757 68.3%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   ALEMBIC PHARMA  STRIDES PHARMA SCIENCE  J.B.CHEMICALS  ASTRAZENECA PHARMA  DIVIS LABORATORIES  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Momentum Moves: The Week Gone By(Momentum Moves)

Nifty and Sensex ended the week gaining 0.60% and 0.52% respectively. Bulls started the week roaring but since Wednesday, the momentum seemed to be tiring.

Related Views on News

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

WOCKHARDT LTD. Announces Quarterly Results (3QFY19); Net Profit Down 80.6% (Quarterly Result Update)

Jan 29, 2019 | Updated on Jan 29, 2019

For the quarter ended December 2018, WOCKHARDT LTD. has posted a net profit of Rs 769 m (down 80.6% YoY). Sales on the other hand came in at Rs 10 bn (up 4.0% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 5-YR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS